03:07:49 EDT Tue 04 Oct 2022
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

News for U:AZN from 2021-10-05 to 2022-10-04 - 78 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2022-10-03 07:15U:AZNNews ReleaseAlexion, AstraZeneca Rare Disease to Acquire LogicBio(TM) Therapeutics to Accelerate Growth in Genomic Medicine
2022-09-16 07:10U:AZNNews ReleaseDanicopan (ALXN2040) Add-On to ULTOMIRIS(TM) (ravulizumab-cwvz) or SOLIRIS(TM) (eculizumab) Met Primary Endpoint in ALPHA Phase III Trial for Patients with Paroxysmal Nocturnal Hemoglobinuria Who Experience Clinically Significant Extravascular Hemolysis
2022-09-15 12:00U:AZNNews ReleaseAstraZeneca Partners with Jeff Bridges, Kumail Nanjiani, and Emily V. Gordon to Educate the Immunocompromised Community about Added Protection Against COVID-19
2022-09-12 11:05U:AZNNews ReleaseIMFINZI(TM) (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up
2022-09-11 09:35U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
2022-09-11 08:05U:AZNNews ReleaseIMFINZI(TM) (durvalumab) and tremelimumab with chemotherapy demonstrated sustained survival benefit in metastatic non-small cell lung cancer, nearly doubling the number of patients alive after three years vs. chemotherapy
2022-09-11 08:00U:AZNNews ReleaseTAGRISSO(TM) (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer
2022-09-09 08:00U:AZNNews ReleaseLYNPARZA(TM) (olaparib) in Combination with Bevacizumab, and as a Monotherapy, Demonstrates Clinically Meaningful Survival Benefit in 1st-Line Advanced Ovarian Cancer Across Two Phase III Trials
2022-09-05 07:00U:AZNNews ReleaseIMFINZI(TM) (durvalumab) Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients with Advanced Biliary Tract Cancer
2022-08-27 10:59U:AZNNews ReleaseNew data show FARXIGA significantly lowers the risk of cardiovascular death in patients with heart failure
2022-08-24 07:00U:AZNNews ReleaseAstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022
2022-08-16 07:00U:AZNNews ReleaseLYNPARZA(TM) (olaparib) in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer
2022-08-12 07:00U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
2022-08-08 06:02U:AZNNews ReleaseHUTCHMED and AstraZeneca Announce that TAGRISSO(TM) Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial
2022-08-05 20:06U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
2022-08-05 14:20U:AZNNews ReleaseCALQUENCE(TM) (acalabrutinib) tablet formulation approved in the US across current indications
2022-07-25 07:00U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low metastatic breast cancer
2022-06-30 07:00U:AZNNews ReleaseIMFINZI(TM) (durvalumab) Plus Chemotherapy Significantly Improved Pathologic Complete Response in AEGEAN Phase III Trial in Resectable Non-Small Cell Lung Cancer
2022-06-23 08:35U:AZNNews ReleaseALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilization From Tissues, Potentially Closing Treatment Gaps for Wilson Disease Community
2022-06-21 07:05U:AZNNews ReleasePROpel Phase III Trial Positive Results of LYNPARZA(TM) (olaparib) Plus Abiraterone in 1st-line Metastatic Castration-resistant Prostate Cancer Published in New England Journal of Medicine Evidence
2022-06-21 07:00U:AZNNews ReleaseEplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the NEURO-TTRansform Phase III Trial for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)
2022-06-05 08:10U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2-Low Metastatic Breast Cancer with HR-Positive and HR-Negative Disease
2022-06-04 10:00U:AZNNews ReleaseCALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line Chronic Lymphocytic Leukemia with 90% of Patients Surviving Five Years in ELEVATE-TN Trial
2022-05-27 09:00U:AZNNews ReleaseFirst Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis
2022-05-23 07:00U:AZNNews ReleaseAstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022
2022-05-15 13:24U:AZNNews ReleasePT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma
2022-05-13 16:21U:AZNNews ReleaseBaili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination with Tagrisso(TM) in Patients with Non-Small Cell Lung Cancer
2022-05-12 09:54U:AZNNews ReleaseDeutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing
2022-05-12 09:00U:AZNNews ReleaseAstraZeneca Joins Accumulus Synergy as a Sponsor to Accelerate the Delivery of Medicines to Patients
2022-05-05 08:58U:AZNNews ReleaseInternational companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 10th and 11th, 2022
2022-05-05 07:00U:AZNNews ReleaseULTOMIRIS(TM) (ravulizumab-cwvz) Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum Disorder
2022-05-05 07:00U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
2022-05-04 08:00U:AZNNews ReleaseImfinzi Plus Chemotherapy Granted Priority Review in the US for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial
2022-04-28 07:00U:AZNNews ReleaseULTOMIRIS(TM) (ravulizumab-cwvz) Approved in the US for Adults with Generalized Myasthenia Gravis
2022-04-25 08:00U:AZNNews ReleaseTremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with Imfinzi
2022-04-19 07:00U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
2022-04-18 08:03U:AZNNews ReleaseAmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and Japan
2022-04-08 13:00U:AZNNews ReleaseBlueprint Medicines Announces BLU-945 Proof-of-Concept Data Supporting Initiation of Comprehensive Combination Development Strategy in EGFR-mutant Non-Small Cell Lung Cancer
2022-04-06 07:00U:AZNNews ReleaseULTOMIRIS(TM) (ravulizumab-cwvz) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeks
2022-04-04 13:54U:AZNNews ReleasePGA Champion Jason Day Launches Getting Out of the Rough Video Series With AstraZeneca to Support Lung Cancer Biomarker Testing Awareness
2022-03-24 07:00U:AZNNews ReleaseAstraZeneca Announces New Partnership with The National Fish and Wildlife Foundation to Plant One Million Trees
2022-03-21 07:00U:AZNNews ReleaseEVUSHELD(TM) long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies
2022-03-16 13:30U:AZNNews ReleaseLYNPARZA(TM) (olaparib) reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer
2022-03-06 23:30U:AZNNews ReleaseHUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS(TM) in Lung Cancer
2022-02-22 02:01U:AZNNews ReleaseHONEYWELL TEAMS WITH ASTRAZENECA TO DEVELOP NEXT-GENERATION RESPIRATORY INHALERS THAT USE NEAR-ZERO GLOBAL WARMING POTENTIAL PROPELLANT
2022-02-21 11:15U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients with HER2-Low Metastatic Breast Cancer
2022-02-14 17:00U:AZNNews ReleaseLYNPARZA(TM) (olaparib) plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer
2022-02-10 17:00U:AZNNews ReleaseAstraZeneca PLC – ADR to Join the NASDAQ-100 Index Beginning February 22, 2022
2022-01-24 07:10U:AZNNews ReleaseEplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis
2022-01-18 17:50U:AZNNews ReleaseIMFINZI ® (durvalumab) Plus Tremelimumab Demonstrated Unprecedented Survival in 1st-line Unresectable Liver Cancer With 31% of Patients Alive at Three Years
2022-01-18 17:20U:AZNNews ReleaseIMFINZI ® (durvalumab) Plus Chemotherapy Reduced Risk of Death by 20% in 1st-Line Advanced Biliary Tract Cancer
2022-01-17 04:00U:AZNNews ReleaseCORRECTING and REPLACING ENHERTU ® granted Priority Review in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
2022-01-13 07:05U:AZNNews ReleaseAstraZeneca Aims to Redefine Liver, Biliary Tract and Prostate Cancer Treatment With Practice-Changing IMFINZI ® (durvalumab) and LYNPARZA ® (olaparib) Data at ASCO GI and GU
2022-01-13 07:00U:AZNNews ReleaseTEZSPIRE Now Available in the United States for the Treatment of Severe Asthma
2022-01-10 16:30U:AZNNews ReleaseFusion Pharmaceuticals Announces Nomination of First Targeted Alpha Therapy Candidate in Collaboration with AstraZeneca to Advance into IND-Enabling Studies for Phase 1 Development
2021-12-16 09:58U:AZNNews ReleaseEVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in independent FDA study
2021-12-13 19:55U:AZNNews ReleaseSamsung Biologics and AstraZeneca expand strategic manufacturing partnership to include COVID-19 and cancer therapy
2021-12-12 10:00U:AZNNews ReleaseCALQUENCE reduced the risk of disease progression or death by 71% vs. standard of care combinations at three years in the ASCEND Phase III trial
2021-12-09 10:05U:AZNNews ReleaseENHERTU ® (fam-trastuzumab deruxtecan-nxki) Additional Analyses Further Reinforce Ground-breaking Efficacy in Patients With HER2-positive Metastatic Breast Cancer
2021-12-08 19:37U:AZNNews ReleaseEVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19
2021-12-03 07:00U:AZNNews ReleaseAstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 With New Data Underscoring Ambition to Redefine Cancer Care
2021-11-30 06:30U:AZNNews ReleaseLYNPARZA ® (olaparib) Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer
2021-11-29 22:00U:AZNNews ReleaseGenetron Health Announces Co-Development Agreement with AstraZeneca R&D China for Personalized MRD Tests for Solid Tumors in China
2021-11-23 19:00U:AZNNews ReleaseHUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS ® and TAGRISSO ® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy
2021-11-19 10:59U:AZNNews ReleaseDeutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing
2021-11-19 09:54U:AZNNews ReleaseDeutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing
2021-11-18 07:00U:AZNNews ReleaseNew Analyses of Two AZD7442 COVID-19 Phase III Trials in High-Risk Populations Confirm Robust Efficacy and Long-Term Prevention
2021-11-17 10:03U:AZNNews ReleaseLOKELMA ® Granted Fast Track Designation in the US to Reduce Cardiovascular Outcomes in Patients on Chronic Hemodialysis With Hyperkalemia
2021-11-11 08:35U:AZNNews ReleaseInternational companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 16th and 17th, 2021
2021-11-05 07:00U:AZNNews ReleaseAstraZeneca Advances Ambition to Redefine Care for Blood Cancer at ASH 2021
2021-11-03 08:00U:AZNNews ReleaseIntegral Molecular Enters into Antibody License Agreement with AstraZeneca for Oncology Therapeutics
2021-11-01 11:08U:AZNNews ReleaseSAPHNELO Consistently Reduces Systemic Lupus Erythematosus Disease Activity Regardless of Disease Duration and Prior Treatment
2021-11-01 07:00U:AZNNews ReleaseAstraZeneca Awards 30 Nonprofit Organizations through the ACT on Health Equity Community Solutions Challenge to Actively Address Health Disparities
2021-10-25 16:21U:AZNNews ReleaseIMFINZI Plus Chemotherapy Significantly Improved Overall Survival in 1st-Line Advanced Biliary Tract Cancer in TOPAZ-1 Phase III Trial at Interim Analysis
2021-10-20 09:00U:AZNNews ReleaseAstraZeneca Announces Winners and Recognizes Oncology Change Makers in Third Annual Cancer Community Awards
2021-10-15 07:00U:AZNNews ReleaseIMFINZI Plus Tremelimumab Significantly Improved Overall Survival in HIMALAYA Phase III Trial in 1st-Line Unresectable Liver Cancer
2021-10-08 07:00U:AZNNews ReleaseTezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis
2021-10-05 07:00U:AZNNews ReleaseAZD7442 Request for Emergency Use Authorization for COVID-19 Prophylaxis Filed in US